LYMPHIR therapy expands to Europe via Named Patient Programs after US launch, increasing global patient access.

Citius Oncology has begun shipping LYMPHIR, a targeted therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), to Europe through regional partners under Named Patient Programs, following its US FDA approval and commercial launch. This expansion allows eligible patients in Europe access to LYMPHIR despite the lack of formal marketing authorization there. The move supports Citius Oncology's strategy to broaden treatment availability for patients with limited options while continuing to grow LYMPHIR's presence in the US market. The therapy works by targeting IL-2 receptors on cancer cells and has shown promise in depleting regulatory T cells and fighting tumors.